Alexion Pharmaceuticals, Inc. Company Profile

✉ Email this page to a colleague

« Back to Dashboard

Summary for Alexion Pharmaceuticals, Inc.

Patents:	10
Tradenames:	5
Ingredients:	5
BLAs:	5

Biologic Drugs for Alexion Pharmaceuticals, Inc.

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Patent Expiration
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	2007-03-16		See Plans and Pricing
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	2007-03-16	6,355,245	See Plans and Pricing
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	2007-03-16	9,718,880	See Plans and Pricing
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	2007-03-16	9,732,149	See Plans and Pricing
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.